2023-10-13 07:00:00
Boehringer launches phase III once morest obesity
The German laboratory Boehringer Ingelheim and his partner Zealand Pharmaa Danish biotech, announced the launch of three phases III evaluating the survodutide (BI 456906) in people suffering from overweight or obesity, with or without diabetes, cardiovascular disease and chronic kidney disease. During the 46-week phase II, study participants lost 19% of their weight.
Long-term effectiveness for Nexviazyme
Sanofi shared new data regarding its Nexviadyme (avalglucosidase alpha) for the treatment of Pompe disease, a rare, progressive and debilitating muscular disease. This replacement drug, approved by the EMA and the FDA, has proven effective in patients for three years, to counter the deficiency of the lysosomal enzyme alpha-acid glucosidase (GAA), characteristic of the disease.
VOS INDICES
source
Semaglutide effective faster than expected
Phase III evaluating the semaglutide of Novo Nordisk for the prevention of kidney failure in people with diabetes will be stopped earlier than planned. After an interim analysis, the independent data monitoring committee supported an early termination of the trial, due to the efficacy results already achieved. Final results are expected in the first half of 2024.
Selected for you
1697238605
#Boehringer #Ingelheim #Sanofi #Novo #Nordisk
